While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder.

Remember Arthur? The aardvark that helped you know how to SPELL aardvark? This PBS show is still running and I think it's ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

The biotech’s lead drug candidate is in Phase 3 testing in Prader-Willi syndrome, a genetic disorder that causes persistent hunger leading to overeating.

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are acting as joint book running managers for the offering.

The Street Fighter movie has picked up a new director – and this choice may be quite unusual. Legendary Pictures first picked ...

Shares of obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) closed 11% lower following a $94M initial public offering. Read more here.

The F-111 Aardvark’s fuselage could lug bomb loads up to 31,000 pounds and fuel for missions up to 2,500 miles long. When the ...